首页> 外文期刊>Clinical Medicine Insights: Gastroenterology >Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome
【24h】

Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome

机译:腹泻型肠易激综合征患者血清源性牛免疫球蛋白分离蛋白的评价

获取原文
           

摘要

Background: There is increased interest in combining nutritional modalities with pharmacological therapies for managing patients with diarrhea-predominant IBS (IBS-D).Aim: A randomized, double-blind, placebo-controlled study to evaluate the impact of oral serum-derived bovine immunoglobulin/protein isolate (SBI) on gastrointestinal symptom scores and quality of life (QoL) in subjects with IBS-D.Methods: Study subjects previously diagnosed with IBS-D according to ROME II criteria were recruited from London, Ontario, Canada and assigned to receive 5 g/day SBI, 10 g/day SBI, or placebo for 6 weeks. Daily symptom frequency and severity scores and a modified IBS-36 questionnaire assessed the impact of nutritional intervention. Laboratory assessments were performed at screening and end of treatment (EOT) to evaluate safety. Within-group comparisons of changes in number of days per week with symptoms and symptom severity were conducted on the per-protocol population of subjects using a t-test.Results: Subjects who received SBI at 10 g/day (N = 15) had statistically significant within-group reductions in abdominal pain (p , 0.01), loose stools (p , 0.01), bloating (p , 0.05), flatulence (p , 0.01), urgency (p , 0.05) and any symptom (p , 0.01) at EOT vs. baseline. Subjects receiving 5 g/day of SBI (N = 15) realized statistically significant within-group reductions in days with flatulence (p , 0.035), incomplete evacuation (p , 0.05), and any symptom (p , 0.01). There were no significant changes in QoL scores or in hematology or clinical chemistry among treatment groups.Conclusions: This pilot study showed that nutritional therapy with either 10 g/day or 5 g/day of SBI in 30 patients was well tolerated and resulted in statistically significant within group improvements in both symptom days and in daily symptom scores in subjects with IBS D. Additional studies are underway with larger numbers of subjects to validate these findings.
机译:背景:将营养形式与药物治疗相结合以治疗腹泻为主的IBS(IBS-D)的兴趣日益浓厚。目的:一项随机,双盲,安慰剂对照研究,以评估口服血清衍生牛的影响免疫球蛋白/蛋白质分离物(SBI)对IBS-D患者胃肠道症状评分和生活质量(QoL)的研究方法:从加拿大伦敦安大略省伦敦市招募并根据ROME II标准诊断为IBS-D的研究对象接受5克/天SBI,10克/天SBI或安慰剂治疗6周。每日症状频率和严重程度评分以及经过修改的IBS-36问卷评估了营养干预的影响。在筛选和治疗结束(EOT)时进行实验室评估以评估安全性。使用t检验对每个方案的受试者群体进行每周天数变化与症状和症状严重程度的组内比较。结果:接受SBI剂量为10 g /天(N = 15)的受试者组内腹部疼痛(p,0.01),大便稀疏(p,0.01),腹胀(p,0.05),肠胃气胀(p,0.01),尿急(p,0.05)和任何症状(p,0.01)的减少具有统计学意义)的EOT与基准。每天接受5 g SBI(N = 15)的受试者在肠胃气胀(p,0.035),不完全排空(p,0.05)和任何症状(p,0.01)的日子里实现了组内统计学上的显着减少。结论:这项初步研究表明,在30例患者中,以10 g /天或5 g /天的SBI进行营养治疗具有良好的耐受性,并进行统计学处理IBS D受试者的症状天数和每日症状评分在小组内均有显着改善。正在进行更多的研究以验证这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号